Xeris Biopharma Holdings, Inc. (XERS)

NASDAQ: XERS · IEX Real-Time Price · USD
2.210
+0.170 (8.33%)
At close: Mar 28, 2024, 4:00 PM
2.190
-0.020 (-0.90%)
After-hours: Mar 28, 2024, 7:55 PM EDT
8.33%
Market Cap 286.52M
Revenue (ttm) 163.91M
Net Income (ttm) -62.26M
Shares Out 140.45M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,193,526
Open 2.130
Previous Close 2.040
Day's Range 2.110 - 2.280
52-Week Range 1.360 - 3.260
Beta 1.21
Analysts Strong Buy
Price Target 4.88 (+120.81%)
Earnings Date Mar 6, 2024

About XERS

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2018
Employees 377
Stock Exchange NASDAQ
Ticker Symbol XERS
Full Company Profile

Financial Performance

In 2023, XERS's revenue was $163.91 million, an increase of 48.68% compared to the previous year's $110.25 million. Losses were -$62.26 million, -34.23% less than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for XERS stock is "Strong Buy." The 12-month stock price forecast is $4.88, which is an increase of 120.81% from the latest price.

Price Target
$4.88
(120.81% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ...

22 days ago - Business Wire

Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

22 days ago - Business Wire

Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

4 weeks ago - Business Wire

Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

7 weeks ago - Business Wire

Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ...

2 months ago - Business Wire

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ...

2 months ago - Business Wire

Xeris Biopharma Updates Its Outlook for 2023

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

3 months ago - Business Wire

Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

3 months ago - Business Wire

Xeris Biopharma Reports Third Quarter 2023 Financial Results

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ...

5 months ago - Business Wire

Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ...

5 months ago - Business Wire

Xeris Biopharma Announces Private Convertible Note Exchange Transactions

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

6 months ago - Business Wire

Xeris to Participate in the 2023 Cantor Global Healthcare Conference

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

7 months ago - Business Wire

Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

7 months ago - Business Wire

Xeris Biopharma Reports Second Quarter 2023 Financial Results

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ...

8 months ago - Business Wire

Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

8 months ago - Business Wire

Xeris Ships One Millionth Gvoke® Unit

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

8 months ago - Business Wire

Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

10 months ago - Business Wire

Xeris Biopharma to Participate at the Jefferies Healthcare Conference

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

10 months ago - Business Wire

Xeris Biopharma Reports First Quarter 2023 Financial Results

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

11 months ago - Business Wire

Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

11 months ago - Business Wire

Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

1 year ago - Business Wire

Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ...

1 year ago - Business Wire

Xeris Biopharma Appoints Ricki Fairley to Board of Directors

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing in...

1 year ago - Business Wire

Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

1 year ago - Business Wire

Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

1 year ago - Business Wire